0000950170-23-027151.txt : 20230609 0000950170-23-027151.hdr.sgml : 20230609 20230609085458 ACCESSION NUMBER: 0000950170-23-027151 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230608 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20230609 DATE AS OF CHANGE: 20230609 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ovid Therapeutics Inc. CENTRAL INDEX KEY: 0001636651 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 465270895 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38085 FILM NUMBER: 231003982 BUSINESS ADDRESS: STREET 1: 441 NINTH AVENUE, 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10001 BUSINESS PHONE: 212-776-4381 MAIL ADDRESS: STREET 1: 441 NINTH AVENUE, 14TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10001 8-K 1 ovid-20230608.htm 8-K 8-K
0001636651false00016366512023-06-082023-06-08

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 08, 2023

 

 

Ovid Therapeutics Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-38085

46-5270895

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

441 Ninth Avenue

14th Floor

 

New York, New York

 

10001

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 646 661-7661

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

OVID

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

Ovid Therapeutics Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) on June 8, 2023. As of April 13, 2023, the record date for the Annual Meeting, there were 70,521,340 shares of Company common stock outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 61,294,999 shares, or 86.91%, were present in person or represented by proxy, which constituted a quorum. Summarized below are descriptions of the proposals voted on at the Annual Meeting and the final results for each of the proposals. The proposals set forth below are described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 27, 2023 (the “Proxy Statement”).

Proposal 1: The Company’s stockholders elected all of the nominees for director to serve a three-year term until the Company’s 2026 annual meeting of stockholders, or until their respective successors are duly elected and qualified, by the votes set forth in the table below:

Nominee

For

Withheld

Broker Non-Votes

Karen Bernstein

39,704,019

 

 

 

5,131,900

 

 

 

16,459,080

 

Jeremy M. Levin

 

44,455,812

 

 

 

380,107

 

 

 

16,459,080

 

 

Proposal 2: The Company’s stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers, as disclosed in the Proxy Statement, by the votes set forth in the table below:

 

For

Against

Abstain

Broker Non-Votes

44,681,350

 

 

 

113,666

 

 

 

40,903

 

 

16,459,080

 

 

 

Proposal 3: The Company’s stockholders recommended, on an advisory basis, a frequency of “one year” for the advisory vote to approve the compensation paid to the Company’s named executive officers by the votes set forth in the table below:

 

One Year

Two Year

Three Year

Abstain

 

Broker Non-Votes

44,015,622

 

 

 

11,727

 

 

 

793,928

 

 

14,642

 

16,459,080

 

 

 

After taking into consideration the foregoing voting results and the prior recommendation of the Company’s Board of Directors (the “Board”) in favor of an annual advisory stockholder vote on the compensation of the Company’s named executive officers (“Say-on-Pay”), the Board has determined that the Company will hold future advisory Say-on-Pay Votes on an annual basis. The Company will continue to hold votes on Say-on-Pay on an annual basis until the occurrence of the next stockholder advisory vote on the frequency of Say-on-Pay, which will occur no later than the Company’s 2029 annual meeting of stockholders.

Proposal 4: The Company’s stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023 by the votes set forth in the table below:

For

Against

Abstain

61,226,349

 

65,728

 

2,922

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

OVID THERAPEAUTICS INC.

 

 

 

 

Date:

June 9, 2023

By:

/s/ Thomas M. Perone

 

 

 

Thomas M. Perone
General Counsel, Corporate Secretary

 


EX-101.SCH 2 ovid-20230608.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 3 ovid-20230608_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 4 ovid-20230608_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document And Entity Information
Jun. 08, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 08, 2023
Entity Registrant Name Ovid Therapeutics Inc.
Entity Central Index Key 0001636651
Entity Emerging Growth Company false
Securities Act File Number 001-38085
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 46-5270895
Entity Address, Address Line One 441 Ninth Avenue
Entity Address, Address Line Two 14th Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10001
City Area Code 646
Local Phone Number 661-7661
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol OVID
Security Exchange Name NASDAQ
XML 6 ovid-20230608_htm.xml IDEA: XBRL DOCUMENT 0001636651 2023-06-08 2023-06-08 0001636651 false 8-K 2023-06-08 Ovid Therapeutics Inc. DE 001-38085 46-5270895 441 Ninth Avenue 14th Floor New York NY 10001 646 661-7661 false false false false Common Stock, par value $0.001 per share OVID NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.ovidrx.com/20230608/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports ovid-20230608.htm ovid-20230608.xsd ovid-20230608_lab.xml ovid-20230608_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ovid-20230608.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "ovid-20230608.htm" ] }, "labelLink": { "local": [ "ovid-20230608_lab.xml" ] }, "presentationLink": { "local": [ "ovid-20230608_pre.xml" ] }, "schema": { "local": [ "ovid-20230608.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ovid", "nsuri": "http://www.ovidrx.com/20230608", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "ovid-20230608.htm", "contextRef": "C_42597965-1b29-454e-aceb-adb8bdfd108c", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.ovidrx.com/20230608/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "ovid-20230608.htm", "contextRef": "C_42597965-1b29-454e-aceb-adb8bdfd108c", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.ovidrx.com/20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.ovidrx.com/20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.ovidrx.com/20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.ovidrx.com/20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.ovidrx.com/20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.ovidrx.com/20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.ovidrx.com/20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.ovidrx.com/20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.ovidrx.com/20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.ovidrx.com/20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.ovidrx.com/20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.ovidrx.com/20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.ovidrx.com/20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.ovidrx.com/20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.ovidrx.com/20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.ovidrx.com/20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.ovidrx.com/20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.ovidrx.com/20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.ovidrx.com/20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.ovidrx.com/20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.ovidrx.com/20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.ovidrx.com/20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.ovidrx.com/20230608/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0000950170-23-027151-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-027151-xbrl.zip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end